PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2397-768X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer ; volume:6 ; number:1 ; day:29 ; month:6 ; year:2022 ; pages:1-6 ; date:12.2022
npj precision oncology ; 6, Heft 1 (29.6.2022), 1-6, 12.2022

Creator: Dillon, Kasia M.
Bekele, Raie T.
Sztupinszki, Zsofia
Hanlon, Timothy
Rafiei, Shahrzad
Szallasi, Zoltan
Choudhury, Atish D.
Mouw, Kent W.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41698-022-00291-7

URN: urn:nbn:de:101:1-2022082020564068741632

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:21 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Dillon, Kasia M.
Bekele, Raie T.
Sztupinszki, Zsofia
Hanlon, Timothy
Rafiei, Shahrzad
Szallasi, Zoltan
Choudhury, Atish D.
Mouw, Kent W.
SpringerLink (Online service)

Other Objects (12)

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Homologous recombination deficiency in breast cancer

Leveraging homologous recombination repair deficiency in sarcoma

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Homologous recombination deficiency in epithelial ovarian cancer

Pan-cancer landscape of homologous recombination deficiency

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Multi-scale characterisation of homologous recombination deficiency in breast cancer

Tumor homologous recombination deficiency assays: another step closer to clinical application?

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Homologous recombination deficiency in breast cancer

Leveraging homologous recombination repair deficiency in sarcoma

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Homologous recombination deficiency in epithelial ovarian cancer

Pan-cancer landscape of homologous recombination deficiency

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Multi-scale characterisation of homologous recombination deficiency in breast cancer

Tumor homologous recombination deficiency assays: another step closer to clinical application?

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Homologous recombination deficiency in breast cancer

Leveraging homologous recombination repair deficiency in sarcoma

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Homologous recombination deficiency in epithelial ovarian cancer

Pan-cancer landscape of homologous recombination deficiency

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Multi-scale characterisation of homologous recombination deficiency in breast cancer

Tumor homologous recombination deficiency assays: another step closer to clinical application?

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read and agree to the privacy policy for the collection of personal data.*

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Show object

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Homologous recombination deficiency in breast cancer

Leveraging homologous recombination repair deficiency in sarcoma

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Homologous recombination deficiency in epithelial ovarian cancer

Pan-cancer landscape of homologous recombination deficiency

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Multi-scale characterisation of homologous recombination deficiency in breast cancer

Tumor homologous recombination deficiency assays: another step closer to clinical application?

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Homologous recombination deficiency in breast cancer

Leveraging homologous recombination repair deficiency in sarcoma

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Homologous recombination deficiency in epithelial ovarian cancer

Pan-cancer landscape of homologous recombination deficiency

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Multi-scale characterisation of homologous recombination deficiency in breast cancer

Tumor homologous recombination deficiency assays: another step closer to clinical application?

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition

Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries

Homologous recombination deficiency in breast cancer

Leveraging homologous recombination repair deficiency in sarcoma

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Homologous recombination deficiency in epithelial ovarian cancer

Pan-cancer landscape of homologous recombination deficiency

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors

Multi-scale characterisation of homologous recombination deficiency in breast cancer

Tumor homologous recombination deficiency assays: another step closer to clinical application?

Related objects

Reset password